Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
48 hedge funds and large institutions have $38.5M invested in Genocea Biosciences, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 54 → 48 (-6)
14% less capital invested
Capital invested by funds: $44.5M → $38.5M (-$6.07M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$266K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$151K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$82.3K |
| 4 |
Renaissance Technologies
New York
|
+$54.5K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.06M |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$343K |
| 3 |
Morgan Stanley
New York
|
-$198K |
| 4 |
Millennium Management
New York
|
-$188K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$128K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Goldman Sachs
New York
| – | -$34K | -4,881 | Closed |
|
52
D.E. Shaw & Co
New York
| – | -$25K | -3,711 | Closed |
|
53
Two Sigma Advisers
New York
| – | -$19K | -2,785 | Closed |
|
54
LPL Financial
San Diego,
California
| – | -$9K | -1,277 | Closed |
|
55
Barclays
London,
United Kingdom
| – | -$4K | -543 | Closed |
|
|
MAM
56
Meeder Asset Management
Dublin,
Ohio
| – | -$2.26K | -330 | Closed |
|
|
TIM
57
Tortoise Investment Management
White Plains,
New York
| – | -$1K | -105 | Closed |
|
58
Simplex Trading
Chicago,
Illinois
| – | +$201 | +38 | New |
|
GNCA Hedge Fund Activity: Q3 2018 in Review
48 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2018, worth a combined $38.5M — down 14% from $44.5M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of GNCA and 8 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was Fosun International, opening a new position worth an estimated $266K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.06M sold.
- 48 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2018, down from 54 in Q2 2018.
- Funds reported $38.5M of Genocea Biosciences, Inc. stock for Q3 2018, down 14% quarter-over-quarter.
- 8 funds opened new Genocea Biosciences, Inc. positions in Q3 2018 and 14 closed out, a net change of -6 holders.
- The largest Genocea Biosciences, Inc. buyer in Q3 2018 was Fosun International, an estimated $266K added.
- The largest Genocea Biosciences, Inc. seller in Q3 2018 was Alyeska Investment Group, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2018.